DOCSLIB.ORG

The BCAR1 Locus in Carotid Intima-Media Thickness and Atherosclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The BCAR1 Locus in Carotid Intima-Media Thickness and Atherosclerosis The BCAR1 Locus in Carotid Intima-Media Thickness and Atherosclerosis Freya Boardman-Pretty University College London Thesis submitted for the degree of Doctor of Philosophy 1 Declaration of work I, Freya Boardman-Pretty, confirm that the work presented in this thesis is my own and has been generated by me as the result of my own original research. Where information has been derived from other sources, this has been indicated in the text. My role in the work presented in each chapter is outlined below. In chapter 3 I carried out all bioinformatics analysis, including identification of SNPs in strong LD, analysis of regulatory marks associated with these SNPs using UCSC Genome Browser, HaploReg and ElDorado, and selection of candidate SNPs. I used the Gene-Tissue Expression (GTEx) browser and Gilad/Pritchard eQTL browser to investigate eQTLs. In chapter 4 I was responsible for genotyping the PLIC cohort for the SNP rs4888378. Genotype data and an analysis plan were sent to Danilo Norata and Andrea Baragetti (University of Milan), who carried out the statistical tests that I requested in PLIC and provided test results and the necessary data for the meta-analysis. I carried out the sex-stratified meta-analysis and additional event rate analysis. In chapter 5 I carried out electrophoretic mobility shift assays (EMSAs) on candidate SNPs, multiplex competitor EMSAs and supershift EMSAs. For the luciferase assay, I designed reporter fragments of interest and carried out the cloning experiments to create the four sets of reporter vectors, and carried out the luciferase assays. I also carried out transfection experiments. In chapter 6 I carried out all experiments involved in design of the 4C protocol. My understanding and design of the protocol was developed with the advice of contacts carrying out similar experiments: Johanna Fischer (Crick Institute), Marjon Verstegen (Hubrecht Institute, Utrecht) and Michal Mokry (UMC Utrecht). In chapter 7 I used exome sequencing data to identify the SNP rs1035539 for study, and carried out genotyping in the IMPROVE and PLIC cohorts. Genotyping data and analysis plan were sent to Danilo Norata and Andrea Baragetti, who carried out the analysis I requested and provided test results. I carried out statistical analysis in IMPROVE. In chapter 8, the pEGFP-C2/BCAR1 and pENTR3C-BCAR1 plasmids had previously been created by the Cardiovascular Biology and Medicine group, and were provided to me for further use. I carried 2 out side-directed mutagenesis, cloning, virus production and assays on transfected and infected cells, with help and guidance from Ian Evans. 3 Acknowledgments Many people gave invaluable help and advice throughout my PhD. I would first like to thank my supervisor Steve Humphries, who from the moment of offering me the PhD position to helping me with the final details of my thesis, has been hugely supportive. His guidance and encouragement have helped me to understand and enjoy new areas of genetics, and motivated me to persevere when things were less easy. Equal thanks go to my secondary supervisor Andrew Smith, whose expertise and knowledge have made a great difference to my PhD, helping me to shape my research and construct much of my thesis. He has always been willing to help me with long and difficult experiments, or to know when I needed to go and complain about them at the pub. Thank you also to Philippa Talmud who has been there for support many times throughout my PhD, and to Ann Walker for the encouraging words during long writing sessions. I am also greatly appreciative towards Jackie Cooper and Fotios Drenos, who have given me a great deal of advice and insight into statistical methods, and were always happy to answer my questions. Thank you to all past and present members of CVG who have made the lab such an enjoyable environment to work in; for being a welcoming and friendly group and for joining in with the bake- offs, plank-offs, cocktail parties, away days and more that make the group such a unique place to be. Thank you to Katherine for always being there to talk about topics both work-related and more inconsequential, Marta for being a constant friend and source of advice, and to Dauda for being my go-to for a chat or for advice on all things technology-related. I am also very grateful to Jutta for all the lab expertise she has shared with me over the years, and to Jay and Jacquie for their help and support. I would like to thank the British Heart Foundation for providing valuable funding to the group to support our research. I would also like to thank the members of the Cardiovascular Biology and Medicine Group, particularly Ian Evans, who has taught me many new methods and has always been on hand to answer my many questions. His tireless support and assistance with both lab work and writing have helped shape a large portion of my thesis. I am very grateful to my collaborators Andrea Baragetti and Danilo Norata, who worked with me on analysis of the PLIC cohort; big thanks to Andrea who was always willing to run new analyses for me and answer all my questions. Thank you too to Karl Gertow and the Karolinska group, who have been excellent collaborators and without whom the basis of this thesis would be very different. 4 I would also like to thank the organisers of the IMPROVE, WHII, EAS and MDC cohorts used in this thesis, and the individuals who participated in these studies. Finally, thank you to my family and friends, who have given me a great deal of support throughout the last few years. I appreciate the patience and encouragement they have shown me and without their help I’m sure I would not be where I am today. 5 Abbreviations AMD: age-related macular degeneration ANOVA: analysis of variance ASAP: Advanced Study of Aortic Pathology BCAR1: breast cancer antiestrogen resistance 1 BiKE: Biobank of Karolinska Endarterectomies BMI: body mass index bp: base pairs BSA: bovine serum albumin CAD: coronary artery disease CCA-IMT: common-carotid intima-media thickness CFDP1: craniofacial development protein 1 CHARGE: Cohorts for Heart and Aging Research in Genomic Epidemiology CHD: coronary heart disease ChIP: chromatin immunoprecipitation ChIP-seq: chromatin immunoprecipitation sequencing CHST6: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 CIP: calf intestinal alkaline phosphatase COS-7: CV-1 (simian) in origin, carrying SV40 CRISPR: clustered regularly-interspaced short palindromic repeats CRP: C-reactive protein CTRB1: chymotrypsinogen B1 CTRB2: chymotrypsinogen B2 DMEM: Dulbecco's modified eagle medium DMSO: dimethyl sulphoxide dNTPs: deoxynucleoside triphosphates EAS: Edinburgh Artery Study EGF: epidermal growth factor EMEM: Eagle's minimal essential medium ENCODE: Encyclopaedia of DNA Elements ER: oestrogen receptor EVS: exome variant server FBS: foetal bovine serum FDR: false discovery rate FH: familial hypercholesterolaemia 6 GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase GFP: green fluorescent protein GTEx browser: Gene-Tissue Expression browser GWAS: genome-wide association study HDL: high density lipoprotein HEK293: human embryonic kidney 293 HR: hazard ratio HR: homologous recombination HUVEC: human umbilical vein endothelial cell IBC: ITMAT-Broad_CARe iCOGS: iSelect Collaborative Oncological Gene-environment Study IMPROVE: European Carotid IMT and IMT-Progression as Predictors of Vascular Events IMT: intima-media thickness KDR: kinase insert domain receptor (aka vascular endothelial growth factor receptor 2) LD: linkage disequilibrium LDHD: lactate dehydrogenase D LDL: low density lipoprotein MAF: minor allele frequency MDC: Malmö Diet and Cancer Study MDS: multi-dimensional scaling NHEJ: non-homologous end joining NRP1: neuropilin-1 nt: nucleotides NTC: no-template control OR: odds ratio PBS: phosphate-buffered saline PBST: phosphate-buffered saline with 0.1% Tween 20 PDGF: platelet-derived growth factor PLIC: Progressione della Lesione Intimale Carotidea SDS: sodium dodecyl sulphate SDS: Sodium dodecyl sulphate SH3: src homology 3 siRNA: short interfering RNA SNAP: SNP Annotation and Proxy Search SOC: super optimal broth with catabolite repression TBE: Tris/Borate/EDTA 7 TE: tris-EDTA TEMED: Tetramethylethylenediamine TF: transcription factor TMEM170A: transmembrane protein 170A VEGF: vascular endothelial growth factor VSMC: vascular smooth muscle cell WHII: Whitehall II ZFP1: zinc finger protein 1 ZNRF1: zinc and ring finger 1 8 Abstract Carotid intima media thickness (IMT) is a marker of subclinical atherosclerosis that can predict cardiovascular events over traditional risk factors. This thesis focused on a chromosome 16 locus associated with IMT and coronary artery disease, in order to identify functional variation affecting protein structure or gene expression, and investigate the role of novel genes in atherosclerosis. Bioinformatics tools were used to identify variants in strong LD with the lead SNP and to filter these to a shortlist of potential regulatory variants. Electrophoretic mobility shift assays on these 6 SNPs detected allele-specific protein binding to the lead SNP rs4888378 in CFDP1, and implicated the protein FOXA. Luciferase reporter assays showed a 35-92% decrease in gene expression with the A allele. Expression-QTL analysis confirmed associations of the protective allele of rs4888378 with higher expression of BCAR1 in vascular tissues. Genotyping and analysis of the lead SNP in the PLIC cohort of 2144 healthy men and women suggested a sex-specific effect of the SNP on IMT progression. Meta-analysis of five cohort studies supported a protective effect of the A allele on common-carotid IMT in women only. As illustrated by this locus, functional variation often lies in enhancers far from its target promoter. Circular chromosome conformation capture (4C) was explored to investigate interactions between enhancers and promoters at this locus, with the aim of capturing regions interacting with rs4888378 and the BCAR1 promoter. Analysis of exome sequencing data identified a SNP in BCAR1 (coding amino acid change P76S), which was genotyped in two cohorts (IMPROVE and PLIC).
Load more

Recommended publications
  • Gene Family: Gene Duplication and Retrotransposon Insertion
    21 Bucentaur (Bcnt)1 Gene Family: Gene Duplication and Retrotransposon Insertion Shintaro Iwashita and Naoki Osada Iwaki Meisei University / National Institute of Genetics Japan 1. Introduction Members of multiple gene families in higher organisms allow for more refined cellular signaling networks and structural organization toward more stable physiological homeostasis. Gene duplication is one the most powerful ways of providing an opportunity to create a novel gene(s) because a novel function might be acquired without the loss of the original gene function (Ohno, 1970). Gene duplication can result from unequal crossing over by recombination, retroposition of cDNA, or whole-genome duplication. Furthermore, a replication-based mechanism of change in gene copy number has been proposed recently (Hastings et al., 2009). Gene duplication generated by retroposition is frequently accompanied by deleterious effects because the insertion of cDNA into the genome is nearly random or unlinks the original gene location resulting in an alteration of the original vital functions of the target genes. Thus retroelements such as transposable elements and endogenous retroviruses have been thought of as “selfish”. On the other hand, gene duplication caused by unequal crossing over generally results in tandem alignment, which less frequently disrupts the functions of other genes. Recent genome-wide studies have demonstrated that retroelements can definitely contribute to the creation of individual novel genes and the modulation of gene expression, which allows for the dynamic diversity of biological systems, such as placental evolution (Rawn & Cross, 2008). It is now recognized that tandem duplication and retroposition are among the key factors that initiate the creation of novel gene family members (Brosius, 2005; Sorek, 2007; Kaessmann, 2010).
    [Show full text]
  • Sample Lab Report
    3030 Venture Lane, Suite 108 ● Melbourne, Florida 32934 ● Phone 321-253-5197 ● Fax 321-253-5199 PATIENT: DOE, JAMES ACCESSION NO: CLINICIAN/ PATIENT ID: REQUESTING DATE OF BIRTH: 1/5/1986 DOCTOR: GENDER: MALE DATE COLLECTED: 5/26/2015 DATE OF REPORT: 6/15/2015 RESULTS PRIMARY TUMOR TYPE RIGHT TESTICLE BIOLOGICALLY IMPORTANT ONCOGENES DETECTED GENE IMPLICATION TP53 TP53 mutations may be an important driver of tumorigenesis and / or a reason for treatment resistance in a some patients. PTEN Responsible for uncontrolled growth. MDM2 Causes p53 inactivation. Associated with cancer growth and progression. TGFB1 TGFB appears to promote tumor progession by stimulating invasion and metastasis. TUBB2A Microtubules are the key components of the cytoskeleton of eukaryotic cells and have an important role in various cellular functions such as intracellular migration and transport, cell shape maintenance, polarity, cell signaling and mitosis. c-JUN Proto-oncogene PHB2 Prohibitins play a crucial role in adhesion processes in the cell and thereby sustaining cancer cell propagation and survival. Clinical Impression: Low Aggressive Potential Additional Genes Detected: ABCG2, ARHGAP5, ATF4, BIRC5, BNIP3, CAPNS1, CARD17, CCNB1, CD24, CDC20, CDK18, CKS2, DCN, DEPDC1, FTL, FZD5, FZD9, GAPDH, GNB2, GPR126, H2AFZ, HDAC1, HMGN2, ID1, IFITM1, JUNB, KPNA2, KRT18, LDHA, LTF, MAD2L1, MAP2K1, MAP2K2, MAP2K4, MAPRE1, MAS1, NME1, NME3, NPM1, PA2G4, PABPC1, PFDN4, PGAM1, PGK1, PHB, PIK3CB, PKM, PPIA, PPIH, PRKX, PRNP, PTMA, RAC1, RAC2, RALBP1, RAP1A, RBBP4, RHOB, RHOC,
    [Show full text]
  • CRKL As a Lung Cancer Oncogene and Mediator Of
    views in The spotliGhT CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to eGFR inhibitors: is it All That it is Cracked Up to Be? Marc Ladanyi summary: Cheung and colleagues demonstrate that amplified CRKL can function as a driver oncogene in lung adeno- carcinoma, activating both RAS and RAP1 to induce mitogen-activated protein kinase signaling. In addition, they show that CRKL amplification may be another mechanism for primary or acquired resistance to epidermal growth factor re- ceptor kinase inhibitors. Cancer Discovery; 1(7); 560–1. ©2011 AACR. Commentary on Cheung et al., p. 608 (1). In this issue of Cancer Discovery, Cheung and colleagues (1) mutual exclusivity. Cheung and colleagues (1) report that present extensive genomic and functional data supporting focal CRKL amplification is mutually exclusive with EGFR focal amplification of the CRKL gene at 22q11.21 as a driver mutation and EGFR amplification. However, of the 6 lung oncogene in lung adenocarcinoma. The report expands on cancer cell lines found in this study to have focal gains of data previously presented by Kim and colleagues (2). CRKL CRKL, 2 contain other major driver oncogenes (KRAS G13D is a signaling adaptor protein that contains SH2 and SH3 in HCC515, BRAF G469A in H1755; refs. 7, 8). Interestingly, domains that mediate protein–protein interactions linking both cell lines demonstrated clear dependence on CRKL in tyrosine-phosphorylated upstream signaling molecules (e.g., functional assays. Perhaps CRKL amplification is more akin BCAR1, paxillin, GAB1) to downstream effectors (e.g., C3G, to PIK3CA mutations, which often, but not always, are con- SOS) (3).
    [Show full text]
  • Conditional Ablation of P130cas/BCAR1 Adaptor Protein
    Camacho Leal et al. Cell Communication and Signaling (2018) 16:73 https://doi.org/10.1186/s12964-018-0289-z RESEARCH Open Access Conditional ablation of p130Cas/BCAR1 adaptor protein impairs epidermal homeostasis by altering cell adhesion and differentiation Maria del Pilar Camacho Leal†, Andrea Costamagna†, Beatrice Tassone, Stefania Saoncella, Matilde Simoni, Dora Natalini, Aurora Dadone, Marianna Sciortino, Emilia Turco, Paola Defilippi, Enzo Calautti‡ and Sara Cabodi*‡ Abstract Background: p130 Crk-associated substrate (p130CAS; also known as BCAR1) is a scaffold protein that modulates many essential cellular processes such as cell adhesion, proliferation, survival, cell migration, and intracellular signaling. p130Cas has been shown to be highly expressed in a variety of human cancers of epithelial origin. However, few data are available regarding the role of p130Cas during normal epithelial development and homeostasis. Methods: To this end, we have generated a genetically modified mouse in which p130Cas protein was specifically ablated in the epidermal tissue. Results: By using this murine model, we show that p130Cas loss results in increased cell proliferation and reduction of cell adhesion to extracellular matrix. In addition, epidermal deletion of p130Cas protein leads to premature expression of “late” epidermal differentiation markers, altered membrane E-cadherin/catenin proteins localization and aberrant tyrosine phosphorylation of E-cadherin/catenin complexes. Interestingly, these alterations in adhesive properties in absence
    [Show full text]
  • Expression Profiling of KLF4
    Expression Profiling of KLF4 AJCR0000006 Supplemental Data Figure S1. Snapshot of enriched gene sets identified by GSEA in Klf4-null MEFs. Figure S2. Snapshot of enriched gene sets identified by GSEA in wild type MEFs. 98 Am J Cancer Res 2011;1(1):85-97 Table S1: Functional Annotation Clustering of Genes Up-Regulated in Klf4 -Null MEFs ILLUMINA_ID Gene Symbol Gene Name (Description) P -value Fold-Change Cell Cycle 8.00E-03 ILMN_1217331 Mcm6 MINICHROMOSOME MAINTENANCE DEFICIENT 6 40.36 ILMN_2723931 E2f6 E2F TRANSCRIPTION FACTOR 6 26.8 ILMN_2724570 Mapk12 MITOGEN-ACTIVATED PROTEIN KINASE 12 22.19 ILMN_1218470 Cdk2 CYCLIN-DEPENDENT KINASE 2 9.32 ILMN_1234909 Tipin TIMELESS INTERACTING PROTEIN 5.3 ILMN_1212692 Mapk13 SAPK/ERK/KINASE 4 4.96 ILMN_2666690 Cul7 CULLIN 7 2.23 ILMN_2681776 Mapk6 MITOGEN ACTIVATED PROTEIN KINASE 4 2.11 ILMN_2652909 Ddit3 DNA-DAMAGE INDUCIBLE TRANSCRIPT 3 2.07 ILMN_2742152 Gadd45a GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 ALPHA 1.92 ILMN_1212787 Pttg1 PITUITARY TUMOR-TRANSFORMING 1 1.8 ILMN_1216721 Cdk5 CYCLIN-DEPENDENT KINASE 5 1.78 ILMN_1227009 Gas2l1 GROWTH ARREST-SPECIFIC 2 LIKE 1 1.74 ILMN_2663009 Rassf5 RAS ASSOCIATION (RALGDS/AF-6) DOMAIN FAMILY 5 1.64 ILMN_1220454 Anapc13 ANAPHASE PROMOTING COMPLEX SUBUNIT 13 1.61 ILMN_1216213 Incenp INNER CENTROMERE PROTEIN 1.56 ILMN_1256301 Rcc2 REGULATOR OF CHROMOSOME CONDENSATION 2 1.53 Extracellular Matrix 5.80E-06 ILMN_2735184 Col18a1 PROCOLLAGEN, TYPE XVIII, ALPHA 1 51.5 ILMN_1223997 Crtap CARTILAGE ASSOCIATED PROTEIN 32.74 ILMN_2753809 Mmp3 MATRIX METALLOPEPTIDASE
    [Show full text]
  • Breast Cancer Antiestrogen Resistance-3 Expression Regulates Breast Cancer Cell Migration Through Promotion of P130cas Membrane Localization Andmembrane Ruffling
    Research Article Breast Cancer Antiestrogen Resistance-3 Expression Regulates Breast Cancer Cell Migration through Promotion of p130Cas Membrane Localization andMembrane Ruffling Randy S. Schrecengost,1 Rebecca B. Riggins,2 Keena S. Thomas,1 Michael S. Guerrero,1 and Amy H. Bouton1 1Department of Microbiology, University of Virginia Health System, Charlottesville, Virginia and 2Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia Abstract antiestrogen resistance-1 (BCAR1; also known as p130Cas; refs. 2, 3). Antiestrogens such as tamoxifen are widely used in the clinic A second protein, BCAR3 (the human homologue of the murine to treat estrogen receptor–positive breast tumors. Resistance protein AND-34), was identified in a genetic screen along with to tamoxifen can occur either de novo or develop over time in BCAR1 as a gene product whose overexpression conferred tamoxifen resistance in vitro (4). BCAR3 is a member of the novel a large proportion of these tumors. Additionally, resistance is S p associated with enhanced motility and invasiveness in vitro. rc homology 2 (SH2)–containing rotein (NSP) family that One molecule that has been implicated in tamoxifen resis- includes two other members, Chat/SHEP1 and NSP1. These tance, breast cancer antiestrogen resistance-3 (BCAR3), has proteins share a common domain structure consisting of an also been shown to regulate migration of fibroblasts. In this amino-terminal SH2 domain and a carboxyl-terminal domain with study, we investigated the role of BCAR3 in breast cancer cell sequence homology to the Cdc25-family of guanine nucleotide exchange factors (GEF). Several studies have shown that BCAR3 migration and invasion.
    [Show full text]
  • 1 Mutational Heterogeneity in Cancer Akash Kumar a Dissertation
    Mutational Heterogeneity in Cancer Akash Kumar A dissertation Submitted in partial fulfillment of requirements for the degree of Doctor of Philosophy University of Washington 2014 June 5 Reading Committee: Jay Shendure Pete Nelson Mary Claire King Program Authorized to Offer Degree: Genome Sciences 1 University of Washington ABSTRACT Mutational Heterogeneity in Cancer Akash Kumar Chair of the Supervisory Committee: Associate Professor Jay Shendure Department of Genome Sciences Somatic mutation plays a key role in the formation and progression of cancer. Differences in mutation patterns likely explain much of the heterogeneity seen in prognosis and treatment response among patients. Recent advances in massively parallel sequencing have greatly expanded our capability to investigate somatic mutation. Genomic profiling of tumor biopsies could guide the administration of targeted therapeutics on the basis of the tumor’s collection of mutations. Central to the success of this approach is the general applicability of targeted therapies to a patient’s entire tumor burden. This requires a better understanding of the genomic heterogeneity present both within individual tumors (intratumoral) and amongst tumors from the same patient (intrapatient). My dissertation is broadly organized around investigating mutational heterogeneity in cancer. Three projects are discussed in detail: analysis of (1) interpatient and (2) intrapatient heterogeneity in men with disseminated prostate cancer, and (3) investigation of regional intratumoral heterogeneity in
    [Show full text]
  • Genomic and Functional Analysis Identifies CRKL As an Oncogene
    Oncogene (2010) 29, 1421–1430 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer YH Kim1,7, KA Kwei1,7, L Girard2, K Salari1,3, J Kao1, M Pacyna-Gengelbach4, P Wang5, T Hernandez-Boussard3, AF Gazdar2, I Petersen6, JD Minna2 and JR Pollack1 1Department of Pathology, Stanford University, Stanford, CA, USA; 2Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA; 3Department of Genetics, Stanford University, Stanford, CA, USA; 4Institute of Pathology, University Hospital Charite´, Berlin, Germany; 5Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA and 6Institute of Pathology, Universita¨tsklinikum Jena, Jena, Germany DNA amplifications, leading to the overexpression of related mortality (Jemal et al., 2008). Nearly 80% oncogenes, are a cardinal feature of lung cancer and of lung cancers diagnosed are non-small-cell lung directly contribute to its pathogenesis. To uncover such cancers (NSCLCs), which are classified into three main novel alterations, we performed an array-based compara- histological subtypes: adenocarcinoma, squamous cell tive genomic hybridization survey of 128 non-small-cell carcinoma and large cell carcinoma. Despite the lung cancer cell lines and tumors. Prominent among our advancement of surgical, cytotoxic and radiological findings, we identified recurrent high-level amplification at treatment options over the years, lung cancer therapy cytoband 22q11.21 in 3% of lung cancer specimens, with remains largely ineffective from a clinical standpoint, another 11% of specimens exhibiting low-level gain spanning as evidenced by a low 5-year survival rate (o15%), that locus.
    [Show full text]
  • Identifying Genetic Risk Factors for Coronary Artery Angiographic Stenosis in a Genetically Diverse Population
    Please do not remove this page Identifying Genetic Risk Factors for Coronary Artery Angiographic Stenosis in a Genetically Diverse Population Liu, Zhi https://scholarship.miami.edu/discovery/delivery/01UOML_INST:ResearchRepository/12355224170002976?l#13355497430002976 Liu, Z. (2016). Identifying Genetic Risk Factors for Coronary Artery Angiographic Stenosis in a Genetically Diverse Population [University of Miami]. https://scholarship.miami.edu/discovery/fulldisplay/alma991031447280502976/01UOML_INST:ResearchR epository Embargo Downloaded On 2021/09/26 20:05:11 -0400 Please do not remove this page UNIVERSITY OF MIAMI IDENTIFYING GENETIC RISK FACTORS FOR CORONARY ARTERY ANGIOGRAPHIC STENOSIS IN A GENETICALLY DIVERSE POPULATION By Zhi Liu A DISSERTATION Submitted to the Faculty of the University of Miami in partial fulfillment of the requirements for the degree of Doctor of Philosophy Coral Gables, Florida August 2016 ©2016 Zhi Liu All Rights Reserved UNIVERSITY OF MIAMI A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy IDENTIFYING GENETIC RISK FACTORS FOR CORONARY ARTERY ANGIOGRAPHIC STENOSIS IN A GENETICALLY DIVERSE POPULATION Zhi Liu Approved: ________________ _________________ Gary W. Beecham, Ph.D. Liyong Wang, Ph.D. Assistant Professor of Human Associate Professor of Human Genetics Genetics ________________ _________________ Eden R. Martin, Ph.D. Guillermo Prado, Ph.D. Professor of Human Genetics Dean of the Graduate School ________________ Tatjana Rundek, M.D., Ph.D. Professor of Neurology LIU, ZHI (Ph.D., Human Genetics and Genomics) Identifying Genetic Risk Factors for Coronary Artery (August 2016) Angiographic Stenosis in a Genetically Diverse Population Abstract of a dissertation at the University of Miami. Dissertation supervised by Professor Gary W.
    [Show full text]
  • Expression of NEDD9 in Hepatocellular Carcinoma and Its Clinical Significance
    ONCOLOGY REPORTS 33: 2375-2383, 2015 Expression of NEDD9 in hepatocellular carcinoma and its clinical significance PENG LU1,2*, ZHI-PENG WANG3*, ZHENG DANG4*, ZHI-GANG ZHENG1*, XIAO LI1, LIANG ZHOU5, RUI DING1, SHU-QIANG YUE1 and KE-FENG DOU1 1Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing Hospital, The Fourth Military Medical University; 2Department of General Surgery, The 518 Central Hospital of PLA; 3Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shanxi; 4Department of Hepatobiliary Surgery, Lanzhou General Hospital of PLA, Lanzhou, Gansu; 5Department of General Surgery, The 155 Central Hospital of PLA, Kaifeng, He'nan, P.R. China Received December 1, 2014; Accepted January 22, 2015 DOI: 10.3892/or.2015.3863 Abstract. Neural precursor cell expressed, developmentally metastasis, intrahepatic venous invasion and high UICC TNM downregulated 9 (NEDD9) plays an integral role in natural and stages in HCC patients. Patients with high NEDD9 expression pathological cell biology. Overexpression of NEDD9 protein levels exhibited poorer recurrence-free and overall survival has been correlated with poor prognosis in various types of than those with a low NEDD9 expression. Additionally, cancer. However, few available data address the precise func- NEDD9 expression status was an independent prognostic tion of the NEDD9 gene in hepatocellular carcinoma (HCC). factor for survival. This correlation remained significant in In the present study, we investigated NEDD9 expression patients with early-stage HCC or with normal serum AFP in 40 primary human HCC tissues compared with matched levels. The results of this study suggest that NEDD9 may be a adjacent non-tumor hepatic tissues using RT-qPCR and valuable prognostic biomarker for HCC, including early-stage western blot analysis.
    [Show full text]
  • Investigation of the Role of Cbl-B in Leukemogenesis and Migration
    INVESTIGATION OF THE ROLE OF CBL-B IN LEUKEMOGENESIS AND MIGRATION by Karla Michelle Badger-Brown A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Medical Biophysics University of Toronto © Copyright by Karla Michelle Badger-Brown (2009) Investigation of the Role of CBL-B in Leukemogenesis and Migration Doctor of Philosophy, 2009 Karla Michelle Badger-Brown Department of Medical Biophysics University of Toronto ABSTRACT CBL proteins are E3 ubiquitin ligases and adaptor proteins. The mammalian homologs – CBL, CBL-B and CBL-3 show broad tissue expression; accordingly, the CBL proteins play roles in multiple cell types. We have investigated the function of the CBL-B protein in hematopoietic cells and fibroblasts. The causative agent of chronic myeloid leukemia (CML) is BCR-ABL. This oncogenic fusion down-modulates CBL-B protein levels, suggesting that CBL-B regulates either the development or progression of CML. To assess the involvement of CBL-B in CML, bone marrow transduction and transplantation (BMT) studies were performed. Recipients of BCR-ABL-infected CBL-B(-/-) cells succumbed to a CML-like myeloproliferative disease with a longer latency than the wild-type recipients. Peripheral blood white blood cell numbers were reduced, as were splenic weights. Yet despite the reduced leukemic burden, granulocyte numbers were amplified throughout the animals. As well, CBL- B(-/-) bone marrow (BM) cells possessed defective BM homing capabilities. From these results we concluded that CBL-B negatively regulates granulopoiesis and that prolonged latency in our CBL-B(-/-) BMT animals was a function of perturbed homing. To develop an in vitro model to study CBL-B function we established mouse embryonic fibroblasts (MEFs) deficient in CBL-B expression.
    [Show full text]
  • High BCAR1 Expression Is Associated with Early PSA Recurrence in ERG Negative Prostate Cancer Asmus Heumann1†, Nina Heinemann1†, Claudia Hube-Magg1, Dagmar S
    Heumann et al. BMC Cancer (2018) 18:37 DOI 10.1186/s12885-017-3956-3 RESEARCHARTICLE Open Access High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer Asmus Heumann1†, Nina Heinemann1†, Claudia Hube-Magg1, Dagmar S. Lang1, Katharina Grupp2, Martina Kluth1, Sarah Minner1, Christina Möller-Koop1,MarkusGraefen3, Hans Heinzer3, Maria Christina Tsourlakis1, Waldemar Wilczak1, Corinna Wittmer1,FrankJacobsen1,HartwigHuland3, Ronald Simon1* ,ThorstenSchlomm3,4, Guido Sauter1, Stefan Steurer1,PatrickLebok1 and Andrea Hinsch1 Abstract Background: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression. Methods: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion. Results: BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability.
    [Show full text]